Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript

Lauren Nowak

All right. Good morning, and thank you for joining Cynata’s Clinical Trial Results Webinar. Hosting this morning is Chair, Geoff Brooke; CEO, Dr. Kilian Kelly; and Chief Business Officer, Dr. Mathias Kroll, who will take you through the Phase II acute graft-versus-host disease and Phase III osteoarthritis trial results. Then I’ll take questions at the end of the presentation. [Operator Instructions] And lastly, as a reminder, this call is being recorded and will be available on the investor hub very shortly.

I’ll now hand over to Geoff to formally commence.

Geoff Brooke

Thank you, Lauren. Geoff Brooke here, I’m the Chairman of Cynata. And as Lauren said, we have the CEO, Kilian, with us as well as the Chief Business Officer, Mathias. I’m sure like everybody else, we’re quite — more than quite, we’re very disappointed and quite shocked by the results that we’ve seen last week. And then we thought the best thing to do would be following the press release is to do a webinar and lay it all out and allow people to ask questions.

So I’m glad we’ve had so many people take up the offer. And again, I just can’t tell you how disappointed we are. Everybody has put their heart and soul into this for numbers of years, let alone shareholders’ investment in cash, hard-earned cash. So we completely understand that. We’ve in fact, put cash ourselves. So we understand the disappointment, not only from an employee point of view, a clinician point of view, but also a shareholder point of view.